WO2003068977A3 - Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden - Google Patents

Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden Download PDF

Info

Publication number
WO2003068977A3
WO2003068977A3 PCT/EP2002/009354 EP0209354W WO03068977A3 WO 2003068977 A3 WO2003068977 A3 WO 2003068977A3 EP 0209354 W EP0209354 W EP 0209354W WO 03068977 A3 WO03068977 A3 WO 03068977A3
Authority
WO
WIPO (PCT)
Prior art keywords
component
containing active
constructs containing
fusion constructs
active sections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/009354
Other languages
English (en)
French (fr)
Other versions
WO2003068977A2 (de
Inventor
Oliver Gaide
Pascal Schneider
Juerg Tschopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget Switzerland SA
Original Assignee
Apoxis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10205583A external-priority patent/DE10205583A1/de
Priority to EP02806793A priority Critical patent/EP1516054B1/de
Priority to US10/503,999 priority patent/US7736657B2/en
Priority to DE50214059T priority patent/DE50214059D1/de
Priority to AU2002333502A priority patent/AU2002333502A1/en
Application filed by Apoxis SA filed Critical Apoxis SA
Priority to DK02806793.2T priority patent/DK1516054T3/da
Priority to AT02806793T priority patent/ATE450614T1/de
Publication of WO2003068977A2 publication Critical patent/WO2003068977A2/de
Publication of WO2003068977A3 publication Critical patent/WO2003068977A3/de
Anticipated expiration legal-status Critical
Priority to US12/756,268 priority patent/US8501177B2/en
Priority to US13/922,897 priority patent/US8895003B2/en
Priority to US14/521,631 priority patent/US20150098944A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Rekombinantes Fusionsprotein, enthaltend eine Aminosäuresequenz, die umfasst: (a) den Fc-Abschnitt oder einen Teil eines Fc-Abschnitts eines Immunglobulins als Komponente (A) oder eine funktionelle Variante von Komponente (A), (b) den extrazellulären Teil eines TNF-Liganden oder eine Teilsequenz des extrazellulären Teil eines TNF-Liganden als Komponente (B) oder eine funktionelle Variante von Komponente (B) and ggf. (c) einen Übergangsbereich zwischen Komponente (A) and Komponente (B), enthaltend einen Linker.
PCT/EP2002/009354 2002-02-10 2002-08-21 Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden Ceased WO2003068977A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK02806793.2T DK1516054T3 (da) 2002-02-10 2002-08-21 Fusionskonstruktioner der indeholder aktive afsnit af TNF-ligander
AT02806793T ATE450614T1 (de) 2002-02-10 2002-08-21 Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
US10/503,999 US7736657B2 (en) 2002-02-10 2002-08-21 Fusion constructs containing active sections on TNF ligands
DE50214059T DE50214059D1 (de) 2002-02-10 2002-08-21 Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
AU2002333502A AU2002333502A1 (en) 2002-02-10 2002-08-21 Fusion constructs containing active sections of tnf ligands
EP02806793A EP1516054B1 (de) 2002-02-10 2002-08-21 Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
US12/756,268 US8501177B2 (en) 2002-02-10 2010-04-08 Treatment of ectodermal dysplasia with EDA1 fusion proteins
US13/922,897 US8895003B2 (en) 2002-02-10 2013-06-20 Pharmaceutical composition comprising EDA-1 Fusion Protein
US14/521,631 US20150098944A1 (en) 2002-02-10 2014-10-23 Fusion constructs containing active sections of tnf ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10205368 2002-02-10
DE10205368.5 2002-02-10
DE10205583.1 2002-02-11
DE10205583A DE10205583A1 (de) 2002-02-10 2002-02-11 Fusionskonstrukte, enthaltend aktive Abschnitte von TNF-Liganden

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/503,999 A-371-Of-International US7736657B2 (en) 2002-02-10 2002-08-21 Fusion constructs containing active sections on TNF ligands
US10503999 A-371-Of-International 2002-08-21
US12/756,268 Continuation US8501177B2 (en) 2002-02-10 2010-04-08 Treatment of ectodermal dysplasia with EDA1 fusion proteins

Publications (2)

Publication Number Publication Date
WO2003068977A2 WO2003068977A2 (de) 2003-08-21
WO2003068977A3 true WO2003068977A3 (de) 2004-05-27

Family

ID=27735661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009354 Ceased WO2003068977A2 (de) 2002-02-10 2002-08-21 Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden

Country Status (4)

Country Link
US (4) US7736657B2 (de)
EP (1) EP1516054B1 (de)
AU (1) AU2002333502A1 (de)
WO (1) WO2003068977A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017679B2 (en) 2005-08-30 2015-04-28 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
US9499627B2 (en) 2009-08-03 2016-11-22 University Of Miami Method for in vivo expansion of T regulatory cells

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773884B1 (de) 2004-08-03 2012-03-07 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US20110250690A1 (en) * 2008-11-11 2011-10-13 Craig H Randall Microfluidic Embryo and Gamete Culture Systems
AU2010231575B2 (en) 2009-03-30 2013-09-12 Edimer Biotech S.A. Preparation of isolated agonist anti-EDAR monoclonal antibodies
AU2012237456B2 (en) * 2011-04-01 2017-06-29 Universitat Stuttgart Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereof
KR20140043380A (ko) 2011-05-13 2014-04-09 에디머 파마수티걸스, 인코포레이티드 Ｘｌｈｅｄ 표현형의 변경을 위한 조성물 및 방법
BR112015002091A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
JP2015536344A (ja) * 2012-11-14 2015-12-21 エディマー ファーマシューティカルズ インコーポレイテッドＥｄｉｍｅｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 外胚葉異形成症の治療のための組成物及び方法
CA2897826C (en) 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
US10300013B2 (en) 2013-10-22 2019-05-28 Espoirxlhed Sàrl Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
US20220267410A1 (en) 2019-06-24 2022-08-25 Universitat Stuttgart TNFR2 Agonists with Improved Stability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
WO2001049866A1 (de) * 1999-12-30 2001-07-12 Apotech Research And Development Ltd. Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen
US6316256B1 (en) * 2000-01-03 2001-11-13 Tr Associates, L.L.C. Method for protein transfer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1498427E (pt) * 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US7115555B2 (en) * 1998-07-09 2006-10-03 Baylor College Of Medicine Hypohidrotic ectodermal dysplasia genes and proteins
WO2000063253A1 (en) * 1999-04-16 2000-10-26 Amgen Inc. Agp-1 fusion protein compositions and methods
RU2263118C2 (ru) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
JP2003533187A (ja) * 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
WO2001049866A1 (de) * 1999-12-30 2001-07-12 Apotech Research And Development Ltd. Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen
US6316256B1 (en) * 2000-01-03 2001-11-13 Tr Associates, L.L.C. Method for protein transfer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAUM PETER R ET AL: "Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 13, no. 17, 1994, pages 3992 - 4001, XP002264605, ISSN: 0261-4189 *
BODMER J-L ET AL: "The molecular architecture of the TNF superfamily", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 27, no. 1, 1 January 2002 (2002-01-01), pages 19 - 26, XP004332356, ISSN: 0968-0004 *
BULFONE-PAUS S ET AL: "AN INTERLEUKIN-2-IGG-FAS LIGAND FUSION PROTEIN SUPPRESSES DELAYED-TYPE HYPERSENSITIVITY IN MICE BY TRIGGERING APOPTOSIS IN ACTIVATED T CELLS AS A NOVEL STRATEGY FOR IMMUNOSUPPRESSION", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 69, no. 7, 15 April 2000 (2000-04-15), pages 1386 - 1391, XP002942713, ISSN: 0041-1337 *
FANSLOW W C ET AL: "Structural characteristics of CD40 ligand that determine biological function.", SEMINARS IN IMMUNOLOGY. UNITED STATES OCT 1994, vol. 6, no. 5, October 1994 (1994-10-01), pages 267 - 278, XP002264604, ISSN: 1044-5323 *
HOLLER N ET AL: "Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 237, no. 1-2, April 2000 (2000-04-01), pages 159 - 173, XP004192503, ISSN: 0022-1759 *
HOLLER NILS ET AL: "Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 23, no. 4, February 2003 (2003-02-01), pages 1428 - 1440, XP002258597, ISSN: 0270-7306 *
SCHNEIDER P ET AL: "APOPTOSIS INDUCED BY DEATH RECEPTORS", PHARMACEUTICA ACTA HELVETIAE, XX, XX, vol. 74, no. 2/3, March 2000 (2000-03-01), pages 281 - 286, XP001121938, ISSN: 0031-6865 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017679B2 (en) 2005-08-30 2015-04-28 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
US9499627B2 (en) 2009-08-03 2016-11-22 University Of Miami Method for in vivo expansion of T regulatory cells

Also Published As

Publication number Publication date
US20150098944A1 (en) 2015-04-09
EP1516054A2 (de) 2005-03-23
EP1516054B1 (de) 2009-12-02
US8501177B2 (en) 2013-08-06
WO2003068977A2 (de) 2003-08-21
US20100254984A1 (en) 2010-10-07
US20050152872A1 (en) 2005-07-14
US20130295093A1 (en) 2013-11-07
US7736657B2 (en) 2010-06-15
US8895003B2 (en) 2014-11-25
AU2002333502A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
WO2003068977A3 (de) Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
HK1077592A1 (zh) 改进型fc融合蛋白质
WO2005001025A3 (en) Immunoglobulin chimeric monomer-dimer hybrids
EP1053255A4 (de) DREIDIMENSIONALE STRUKTUREN UND MODELLE VON Fc-REZEPTOREN UND IHRE VERWENDUNGEN.
WO2005087810A3 (en) Dimeric fusion proteins and materials and methods for producing them
DK1682583T3 (da) Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf
WO2004065540A3 (en) Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
WO2005047327A8 (en) NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
IL157446A0 (en) Increased recovery of active proteins
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
WO2002002626A3 (en) Novel secreted proteins
WO2004020405A3 (en) Modified transferrin fusion proteins
WO2005005638A3 (en) High affinity fusion proteins (rc-scfv-fc or scfv-scfv-fc) binding cytokines, particularly il-6 & il-18
WO2004041865A3 (en) Stabilized single domain antibodies
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2002010195A3 (en) Modified peptides with increased potency
WO2003068924A3 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2002099119A3 (en) B7-related nucleic acids and polypeptides useful for immunomodulation
WO2006001023A3 (en) Chimeric proteins and uses thereof
WO2004108885A3 (en) Fc chimeric proteins with anti-hiv drugs
WO2002006306A3 (en) SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY
IL166343A0 (en) Igg fc/hiv-gp 120/c3d fusion protein
WO2003072751A3 (en) Expression system for human brain-specific voltage-gated sodium channel, type 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002806793

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10503999

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002806793

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP